STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 2, 1999, and the six-month period ended July 2, 1999. STAAR Surgical Company is a Delaware corporation headquartered in Monrovia, California, specializing in refractive products, including the Implantable Contact Lens (ICL) and Toric intraocular lenses. As of August 10, 1999, the company had 14,081,930 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended July 2, 1999 | Six Months Ended July 3, 1998 |
|---|---|---|
| Total Revenues | $29,556,916 | $28,083,711 |
| Gross Profit | $18,323,838 | $19,972,070 |
| Gross Margin | 62.0% | 71.1% |
| Operating Income | $2,877,176 | $5,474,691 |
| Net Income | $1,349,672 | $3,198,178 |
| Diluted EPS | $0.09 | $0.22 |
| Cash and Cash Equivalents (End of Period) | $3,986,590 | $3,734,705 |
| Net Cash Provided by Operating Activities | $1,155,393 | $4,344,069 |
| Total Debt (Current + Long-term) | $12,610,243 | $N/A (Not explicitly aggregated in text) |
| Current Ratio | 3.0:1 | 2.9:1 (Jan 1, 1999) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 5.2% year-over-year, driven by higher sales of refractive products (ICL and Toric lenses). This was partially offset by lower average selling prices for intraocular lenses (IOLs) due to competitive pressures.
- Margin Compression: Gross profit margin declined from 71.1% to 62.0%. Cost of sales rose to 38.0% of revenue from 28.9%, attributed to lower IOL selling prices and higher unit costs for inventory produced in 1998.
- Profitability Decline: Net income decreased 57.8% to $1.35 million. Operating income dropped 47.4% due to increased marketing expenses for the Toric lens launch and higher interest expenses.
- Cash Flow: Net cash provided by operating activities fell significantly to $1.16 million from $4.34 million, primarily due to a $1.97 million increase in operating working capital.
- Debt Structure: The company renegotiated its credit facility, adding a $4 million term note to its existing $10 million line of credit.
Outlook, Risks, and Management Commentary
- Outlook: Management expects to remain profitable and believes future cash flow needs will be met through operations or additional financing if required.
- Year 2000 Compliance: The company is ahead of schedule for Y2K compliance. Principal hardware and software have been certified or upgraded. Costs incurred to date are immaterial, though risks remain regarding external suppliers and utilities.
- Foreign Operations: Approximately 56% of six-month revenues ($16.65 million) were foreign, primarily from Europe. Risks include fluctuating exchange rates and foreign government regulations.
- Unusual Items: The company recorded a net foreign translation loss of $502,396 for the six-month period. Equity in earnings of the joint venture with Canon STAAR decreased significantly compared to the prior year.
Investor Verification Checklist
- Verify the sustainability of the 5.2% revenue growth given the 9.1% decline in gross margin.
- Confirm the impact of the new $4 million term note on future interest expense and debt covenants.
- Assess the timeline for completing Y2K compliance for foreign subsidiaries scheduled for the third quarter of 1999.
- Review the specific competitive pressures causing lower average selling prices for IOLs.
- Monitor the $1.97 million increase in operating working capital to ensure it does not signal inventory buildup or collection issues.